Figure 1
Flowchart of the study of patients from the newborn cohort with a history of abnormal velocities. Outcome of velocities after first normalization. Chronic transfusion was continued in 7 patients: 1 patient developed conditional velocities after initial normalization on transfusion, 2 patients with an identical donor are awaiting transplant, and 4 patients are scheduled for the switch to hydroxyurea. Chronic transfusion was stopped, and no new treatment introduced in 7 patients. Three of these had hypersplenism and were splenectomized, and it was decided to only observe the outcome. The parents of the 4 other patients refused the switch to hydroxyurea. After transfusion discontinuation, 3 of 7 patients (including 1 splenectomized) had reversion to abnormal TCDI and were placed again on transfusion, but 1 having a genoidentical cord blood donor was later transplanted. Transplant was performed in 17 patients who had a genoidentical donor. They were maintained on transfusion until transplant. All still have normal velocities posttransplant. Switch to hydroxyurea was prescribed in 45 patients (see the text).

Flowchart of the study of patients from the newborn cohort with a history of abnormal velocities. Outcome of velocities after first normalization. Chronic transfusion was continued in 7 patients: 1 patient developed conditional velocities after initial normalization on transfusion, 2 patients with an identical donor are awaiting transplant, and 4 patients are scheduled for the switch to hydroxyurea. Chronic transfusion was stopped, and no new treatment introduced in 7 patients. Three of these had hypersplenism and were splenectomized, and it was decided to only observe the outcome. The parents of the 4 other patients refused the switch to hydroxyurea. After transfusion discontinuation, 3 of 7 patients (including 1 splenectomized) had reversion to abnormal TCDI and were placed again on transfusion, but 1 having a genoidentical cord blood donor was later transplanted. Transplant was performed in 17 patients who had a genoidentical donor. They were maintained on transfusion until transplant. All still have normal velocities posttransplant. Switch to hydroxyurea was prescribed in 45 patients (see the text).

Close Modal

or Create an Account

Close Modal
Close Modal